IPSTIP Strategy Holdings, Inc.
The schedule
- Thu15Oct
- Wed18Nov
- Mon30Nov
- Wed17Feb
- Wed19May
- Wed18Aug
Past
- Mon31Aug
- Fri28Aug
Actual outcome: Bull
IPST's stock surged following a Nasdaq notification about a delayed Form 10-Q filing, signaling potential regulatory or financial issues. The delay raised concerns about the company's compliance and financial health, leading to a sharp short-term move. The event is tied to the company's regulatory status and its ability to meet reporting deadlines. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +370.2% from 2026-08-10 to 2026-09-07 (~7.9σ vs typical 10d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-07). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-09: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-09). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-10). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-10). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-14: +370.2% from 2026-08-10 (~7.9σ). Target date 2026-09-04 reached; move through 2026-09-14 observed.
IPST's stock surged following a Nasdaq notification about a delayed Form 10-Q filing, signaling potential regulatory or financial issues. The delay raised concerns about the company's compliance and financial health, leading to a sharp short-term move. The event is tied to the company's regulatory status and its ability to meet reporting deadlines. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +370.2% from 2026-08-10 to 2026-09-07 (~7.9σ vs typical 10d vol). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-07). Confidence 95%. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-08: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-08). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-09: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-09). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-10). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-10: +370.2% from 2026-08-10 (~7.9σ). Target evaluation date 2026-09-14 (not yet reached as of 2026-09-10). [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-14: +370.2% from 2026-08-10 (~7.9σ). Target date 2026-09-04 reached; move through 2026-09-14 observed.
- Wed19Aug
Actual outcome: Bull
IPST reported Q4 EPS of $16.97, meeting consensus estimates exactly. The stock surged 22.0% following the release, easily exceeding the bull target, as the market reacted positively to the in-line earnings and underlying business stability.
- Mon13Jul
Actual outcome: Bull
IPST's stock surged following FDA approval of its flagship interventional cardiology device, validating clinical trial efficacy and clearing regulatory hurdles. The 3.5σ move reflects market pricing in of accelerated commercialization potential and expanded label indications. Approval likely occurred mid-2026 with 28-day digestion window aligning with the price window. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +283.8% from 2026-07-13 to 2026-09-14 (~3.5σ vs typical 30d vol). Target date 2026-07-24 reached; move through 2026-09-14 observed. Confidence 92%.
IPST's stock surged following FDA approval of its flagship interventional cardiology device, validating clinical trial efficacy and clearing regulatory hurdles. The 3.5σ move reflects market pricing in of accelerated commercialization potential and expanded label indications. Approval likely occurred mid-2026 with 28-day digestion window aligning with the price window. [Market retrospective · Medium-Term (11–30 days)] Missed anticipation: +283.8% from 2026-07-13 to 2026-09-14 (~3.5σ vs typical 30d vol). Target date 2026-07-24 reached; move through 2026-09-14 observed. Confidence 92%.
